Ex-DeepMind's Ryutaro Tanno joins AI biotech Pathos as Chief AI Officer
davidstutz92 · x · 2026-11-18
Ryutaro Tanno is leaving Google DeepMind after 4 years to become Chief AI Officer at AI drug-development company Pathos, which is expanding from oncology into neurology.
- Pathos's AI platform Foundry drives every major decision: which drugs to pursue, which patients to prioritize, and how trials run
- The company owns its drug assets and runs its own clinical trials, feeding real-time clinical and wet-lab data back into Foundry
- Tanno argues this closed loop is key to an AI drug engine where each program teaches the next
More from Companies & People
- Legaltech startups ditch OpenAI: ZDR requires large minimum-spend contracts — thedealdirector · 2026-11-18
- FactSet CEO on making a 48-year-old financial data firm truly AI-native — TiernanRayTech · 2026-11-18
- A step-by-step playbook for making your enterprise AI-native — alex_verem · 2026-11-18
- Five lessons from a year of deploying AI at PE-backed companies — alex_verem · 2026-11-18
- ChatGPT ad clicks worth just $0.26 as Google tests removing AI Mode over weak ad revenue — gaganghotra_ · 2026-11-18
- PyTorch Foundation names 2026 ambassadors spanning Egypt, Kenya and Singapore — PyTorch · 2026-11-18